United States liver
cancer therapeutics market is expected to grow significantly over the coming
years, due to several factors. These factors include the
increasing prevalence of liver cancer, rising demand for effective treatments,
and advancements in targeted therapies and immunotherapies.
According to the
American Cancer Society, in 2023, there will be approximately 41,210 new instances
of primary liver cancer in the United States (27,980 men and 13,230 women).
Hepatocellular
carcinoma, a substitute term for liver cancer, is a kind of cancer that
develops in the cells of the liver. It is an acute disease that could be fatal
and can spread to different body parts. Chronic hepatitis B and C, obesity,
diabetes, and consuming alcohol are some of the major contributors to liver
cancer. The effectiveness of treatment depends upon the stage and severity of
the cancer and includes surgery, chemotherapy, radiation therapy, targeted
therapy, and immunotherapy.
The United States liver
cancer therapeutics market is expanding because of the accessibility of
innovative options for treatment. The development of minimally invasive
surgical procedures like laparoscopic liver removal and radiofrequency ablation
has reduced the invasiveness and increased the effectiveness of liver cancer
therapeutics. The overall survival rate of patients with liver cancer has also
increased because of the use of targeted therapy, immunotherapy, and
combination therapy.
The United States market
for liver cancer therapeutics is expanding because of the accessibility of
innovative drugs. The treatment options for people with liver cancer have
increased because of the approval of novel medications like Sorafenib,
Lenvatinib, and Regorafenib. In clinical studies, these medications produced
encouraging outcomes, and it is anticipated that they will drive market
expansion in the years to come.
Additionally, the market
is expanding because of a growing focus on research and development activities
in the field of liver cancer therapeutics. To create novel medications and
liver cancer treatment strategies, several pharmaceutical companies are making
significant investments in R&D operations. For instance, Stivarga, an
innovative drug being tested in clinical studies by Bayer AG, has showed favorable
results in the management of advanced liver cancer.
The increasing focus on
precision medicine is one of the key trends that will impact the therapeutics
market for liver cancer in the United States in the years to come. Precision
medicine involves altering a patient's treatment based on their genetic
profile, lifestyle, and other variables. This strategy may increase the
efficacy of liver cancer treatment while minimizing negative effects. Precision
medicine's expansion in the treatment of liver cancer is expected to be fueled
by the development of biomarkers and genetic profiling methods.
The rising use of
combination treatments is another development that will have an impact on the
development of the US liver cancer therapies market in the next years.
Combination therapy involves using multiple drugs or methods of
treatment at once to increase the efficacy of the treatment. Combination
therapy has demonstrated outstanding results in trials, and it is expected to
have a more significant part in liver cancer treatment.
In the years to come,
the United States liver cancer therapeutics is expected to grow,
owing to the usage of immunotherapy. In immunotherapy, cancer cells are
combatted by the body's immune system. For the treatment of liver cancer, several
immunotherapy drugs have been granted approval, and more are being researched.
As scientists learn more about the underlying biology of liver cancer, their
understanding of the efficacy of immunotherapy as a liver cancer treatment is
anticipated to grow.
Additionally, in the
coming years, the United States liver cancer therapeutics market is
expected to be significantly affected by the growing use of artificial
intelligence (AI). Huge amounts of medical data can be analyzed using AI to
find patterns that can aid in the detection and management of liver cancer.
Better patient outcomes will be expected because of the employment of AI in the
diagnosis and treatment of liver cancer.
The United States liver
cancer therapeutics market has been significantly impacted by the COVID-19
pandemic. The delay of therapeutic trials for liver cancer has been one of the
pandemic's most important effects. The pandemic caused numerous clinical trials
to be delayed or disbanded which slowed down the development and launch of novel
liver cancer treatments. The epidemic has also interfered with the delivery of
cancer care, notably the treatment of liver cancer, which has caused delays in
diagnosis and treatment as well as decreased patient access to treatment
facilities. Economic difficulties have been brought on by the pandemic,
including decreased funding for research and development projects.
Although the United
States liver cancer therapeutics market is expected to grow in the next
years, there are several challenges that may hinder this growth. The challenges
include the high costs of care, a shortage of effective treatment options, the
lack of understanding of the disease, a shortage of skilled
professionals with expertise in treating liver cancer, and the complexity
of the disease.
Prevalence of Liver
Cancer in United States
The prevalence of liver
cancer is rising in the United States and one of the contributing causes is the
ageing population. The United States liver cancer therapeutics market is
seeing innovation due to the rising incidence of liver cancer. The development
of multiple novel drugs and treatments, such as immunotherapies and targeted
therapies, shows promise in the fight against liver cancer. The market for
these new treatments is expanding due to the rising incidence of liver cancer,
which is encouraging investment in research and development.
The demand for screening
and early detection techniques is also being driven by the rising incidence of
liver cancer. For improved outcomes for patients, liver cancer needs to be
detected early. Several new methods for screening are now being developed and
show potential to do this. Investment in these methods of detection is being
driven by the rising incidence of liver cancer, which will assist to improve
patient outcomes and foster the development of the liver cancer therapeutics
market in United States.
Additionally, there is a
growing demand for supportive care services due to the incidence of liver
cancer. Patients frequently require supportive care to manage symptoms and side
effects of treatment since liver cancer can be challenging to manage. The
demand for these supportive medical services is being driven by the rising
incidence of liver cancer, which will help in the development of the liver
cancer therapeutics market in United States.
Download Free Sample Report
Increasing Research and
Development Investments for the Development of Novel Therapies
In the United States,
the prevalence of liver cancer is rising, and it is a harmful and at times
fatal illness. The illness is frequently challenging to manage, and patients
need a variety of treatment options to control their symptoms and prolong
survival. Fortunately, the United States liver cancer therapeutics market is
expanding and will continue to grow over the next few years owing to rising
expenditures on research and development (R&D) for the development of novel
therapies.
In years to come, the
United States liver cancer therapeutics market is expected to grow due to
rising spending on research and development. Pharmaceutical and biotech
companies are investing an enormous amount of revenue on research and
development to create advance drugs that can help patients have better outcomes
and live longer. These innovative therapies for liver cancer include targeted
drugs, immunotherapies, and combination therapy.
Market Segmentation
The United States liver cancer therapeutics market can
be segmented by cancer type,
therapy, equipment, factors, route of administration, distribution channel, and
region. By cancer type, the United States liver cancer
therapeutics market can be segmented into hepatocellular carcinoma, cholangiocarcinoma,
hepatoblastoma, angiosarcoma, and liver metastasis. Based on therapy, the United
States liver cancer therapeutics market is divided into targeted therapy,
chemotherapy and radiation therapy, immunotherapy, and others. Based on equipment,
the United States liver cancer therapeutics market is divided into computed
radiography, sonography, MRI, and others. Based on factors, the United States liver
cancer therapeutics market is divided into cirrhosis, nonalcoholic fatty liver disease,
excessive alcohol consumption, and others. Based on route of administration,
the market is segmented into oral, intravenous, and others. Based on
distribution channel, the United States liver cancer therapeutics market is
divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Market Players
Bristol-Myers Squibb, Merck & Co., Bayer AG,
Eli Lilly and Company, Novartis International AG, and Ipsen Biopharmaceuticals
Inc. are some of the leading companies operating in the United States liver
cancer therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2022
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units, and CAGR for 2018-2022 and 2023-2028
|
|
Report Coverage
|
Revenue forecast, Volume forecast company share,
competitive landscape, growth factors, and trends
|
|
Segments Covered
|
Cancer Type
Therapy
Equipment
Factors
Route of Administration
Distribution Channel
|
|
Regional Scope
|
Northeast Region; Midwest Region; South Region;
West Region
|
|
Key Companies Profiled
|
Bristol-Myers Squibb, Merck & Co., Bayer AG, Eli Lilly and
Company, Novartis International AG, Ipsen Biopharmaceuticals Inc.
|
|
Customization Scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore
purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide
the editable version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, United States liver cancer
therapeutics market has been segmented into following categories, in addition
to the industry trends which have also been detailed below:
- United States Liver Cancer Therapeutics Market, By Cancer Type
- Hepatocellular
Carcinoma
- Cholangiocarcinoma
- Hepatoblastoma
- Angiosarcoma
- Liver
Metastasis
- United States Liver Cancer Therapeutics Market, By Therapy
- Targeted
Therapy
- Chemotherapy
and Radiation Therapy
- Immunotherapy
- Others
- United States Liver Cancer Therapeutics Market, By Equipment
- Computed
Radiography
- Sonography
- MRI
- Others
- United States Liver Cancer Therapeutics Market, By Factors
- Cirrhosis
- Nonalcoholic
Fatty Liver Disease
- Excessive
Alcohol Consumption
- Others
- United States Liver Cancer Therapeutics Market, By Route of Administration
- United States Liver Cancer Therapeutics Market, By Distribution Channel
- Hospital
Pharmacies
- Retail
Pharmacies
- Online
Pharmacies
- United States Liver Cancer Therapeutics Market, By Distribution Channel
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in United States liver cancer therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
- Detailed
analysis and profiling of additional market players (up to five).
United States Liver
Cancer Therapeutics Market is an upcoming report to be released soon. If
you wish an early delivery of this report or want to confirm the date of
release, please contact us at [email protected]